Dr. Ghamande on the AIM2CERV Trial in Cervical Cancer

Sharad Ghamande, MD
Published: Friday, Jan 12, 2018



Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the AIM2CERV trial for patients with cervical cancer.

According to Ghamande, the standard of care used to be radiation therapy with external and internal radiation. However, 5 years ago the addition of chemotherapy made a large difference in response rates and overall survival.

Patients with stage II advanced cervical cancer had a disease-free survival of 69% at 3 years. To date, there has not been a big difference made in these numbers, explains Ghamande.

The phase III AIM2CERV study is investigating axalimogene filolisbac (ADXS11-001) as an upfront therapy evaluating its ability to consolidate these patients who are destined to fail, and potentially prevent cervical cancer. Patients on this trial are randomized to ADXS11-001 or a placebo. This is a global trial with 150 sites in over 20 countries.
 
SELECTED
LANGUAGE


Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the AIM2CERV trial for patients with cervical cancer.

According to Ghamande, the standard of care used to be radiation therapy with external and internal radiation. However, 5 years ago the addition of chemotherapy made a large difference in response rates and overall survival.

Patients with stage II advanced cervical cancer had a disease-free survival of 69% at 3 years. To date, there has not been a big difference made in these numbers, explains Ghamande.

The phase III AIM2CERV study is investigating axalimogene filolisbac (ADXS11-001) as an upfront therapy evaluating its ability to consolidate these patients who are destined to fail, and potentially prevent cervical cancer. Patients on this trial are randomized to ADXS11-001 or a placebo. This is a global trial with 150 sites in over 20 countries.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x